stockrow
Saturday 7 November 2026
Export ABPO’s income statement to Excel — free account
Abpro Holdings Inc.
ABPO Healthcare Biotechnology
Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023.
- EPS
- +89.3%
- Free cash flow
- −0.48%
Quarter to June 2026, against a year earlier
0.58
0.02
+3.57%
Follow ABPO
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.52 | 0.61 | 0.03 | 0.04 | |
Current Ratio |
0.62 | 0.74 | 0.10 | 0.07 | |
Net Debt/EBITDA |
3.61 | 5.82 | 0.04 | 0.29 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.12 | 2.02 | (0.11) | 1.71 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.15 | |
Interest Coverage |
(51.09) | (40.57) | (79.04) | (6.92) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.16 | 0.10 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.46) | (0.28) | (1.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Free Cash Flow per Share |
(0.18) | (0.46) | (0.28) | (1.07) | |
Cash per Share |
0.72 | 1.21 | 0.04 | 0.13 | |
Shareholders Equity per Share |
(0.51) | (0.50) | (3.71) | (5.97) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.51) | (0.50) | (3.71) | (5.97) | |
Free Cash Flow |
(1.05) | (2.08) | (0.62) | (2.81) | |
Working Capital |
(3.15) | (2.42) | (8.45) | (16.07) | |
Capital Expenditures |
— | — | 0.00 | 0.03 | |
Net Current Asset Value |
(3.15) | (2.42) | (8.45) | (16.07) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.26 | 0.18 | 0.18 | |
Average Payables |
4.71 | 4.83 | 4.63 | 3.23 | |
Average Assets |
4.36 | 4.83 | 2.86 | 4.78 | |
Average Common Equity |
(9.97) | (10.03) | (11.61) | (16.70) |
Columns are period end dates · fundamentals updated 26 Oct 2026